tbuckley/cabot-search huggingface dataset:
FRI0096 Haq baseline values in an international registry of ra patients during the era of biologic terapies: the 2013 meteor database.
Authors: G. Ferraccioli, G. Lapadula, M. Dougados, D. J. Veale, T. W. Huizinga, C. F. Allaart, R. B. Landewé, J. A. P. Da Silva, E. Martin Mola, R. J. Moots, J. Kay, K. I. Salomon-Escoto, D. van der Heijde
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> HAQ score is a major index of rheumatoid arthritis (RA) disease severity in clinical practice. Data indicate that patients with RA and high HAQ scores (&gt;2) receive disability benefits (1). We investigated the proportion of patients with no and severe disability (HAQ&gt;2) (2,3) during the era of biologic therapies in a large international database. This query provides "real world" data about the burden of disability associated with RA in different clinical settings and in different cohorts. <h3>Objectives</h3> To assess the proportions of RA patients with no and severe disability across various countries. <h3>Methods</h3> The METEOR database is an international database that has recruited RA patients from different countries who are followed in the setting of usual care at various centres. We report the number of patients in this database (Table 1) and we analyzed the proportion of RA patients for whom all values have been entered, considering the different characteristics across participating countries. <h3>Results</h3> Table 1. <h3>Conclusions</h3> This cross-sectional study suggests that, especially in the UK and Italy, RA patients with HAQ scores&lt;0.5 at entry into the database are in the minority and that there remains a not insignificant number of subjects with a HAQ score &gt;2. This suggests that there may still be an opportunity to treat RA more aggressively in some countries. Further studies are warranted to determine whether this reflects barriers to successful treatment of RA that may be inherent in some health care systems or if it is merely an indication of structural damage from past disease activity. <h3>References</h3> Kirwan J et al. British J of Rheum 1986; 25:206-209 Krishnan E et al. Arth Rheum 2004; 50: 953-960 Mancarella L et al. J Rheumatol 2007; 34:1670-1673 <h3>Disclosure of Interest</h3> None Declared
Preserved Insulin Secretion and Insulin Independence in Recipients of Islet Autografts
Authors: Kathryn L. Pyzdrowski, David M. Kendall, Jeffrey B. Halter, Raouf E. Nakhleh, David E.R. Sutherland, R. Paul Robertson
Journal: New England Journal of Medicine (1992)

Transplantation of pancreatic islets, rather than whole pancreas, has been introduced as a treatment for diabetes mellitus. We studied five patients ranging in age from 12 to 37 years who had severe chronic pancreatitis for which they underwent total pancreatectomy followed by isolation and hepatic transplantation of their own islets.
A Deficiency of Carnitine–Acylcarnitine Translocase in the Inner Mitochondrial Membrane
Authors: Charles A. Stanley, Daniel E. Hale, Gerard T. Berry, Susan Deleeuw, Jay Boxer, Jean-Paul Bonnefont
Journal: New England Journal of Medicine (1992)

MITOCHONDRIAL oxidation of fatty acids provides the chief source of energy during prolonged fasting as well as for cardiac muscle and skeletal muscle during exercise. In the past decade, 10 genetic defects of this pathway have been recognized in infants and children.1 2 3 4 5 6 7 Although each of these disorders is rare, failure to recognize them can deprive patients of lifesaving therapy. Patients with these defects present with coma after a period of starvation and have hypoketosis — that is, their serum ketone concentrations are low. They may also have cardiomyopathy and muscle weakness. Three of the disorders affect the carnitine cycle, illustrated . . .
EFFECTS OF STATIN THERAPY ON CORONARY PLAQUE MORPHOLOGY IN PATIENTS WITH ACUTE CORONARY SYNDROME VERSUS STABLE ANGINA PECTORIS
Authors: Rocco Vergallo, Jingbo Hou, Haibo Jia, Yoshiyasu Minami, Tsunenari Soeda, Sining Hu, Shaosong Zhang, Bo Yu, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2015)
FDG PET/CT Evidence of Effective Treatment of Cardiac Sarcoidosis With Adalimumab
Authors: Christina T. Miller, Nadera J. Sweiss, Yang Lu
Journal: Clinical Nuclear Medicine (2016)

A 53-year-old man with mediastinal lymph node biopsy and cardiac MRI–proven cardiac sarcoidosis (CS) received treatment with pacemaker and steroids. FDG PET/CT showed active CS despite treatment with prednisone and methotrexate. Addition of weekly adalimumab (Humira) injections was introduced for 3 months. Follow-up FDG PET/CT showed complete resolution of CS as well as improvement of other sarcoid lesions in the thoracic lymph nodes.
Reserve antidepressants for cases of severe depression, Dutch doctors are told
Authors: T. Sheldon
Journal: BMJ (2012)

Antidepressant drugs such as serotonin reuptake inhibitors (SSRIs) and tricyclic depressants should be prescribed as the first treatment only in cases of severe depression, says new guidance from the Dutch College of General Practitioners.

It recommends that drug treatment should not be “the first step” for patients exhibiting only “depressive symptoms,” a new category distinct from depression—a move that professional associations believe could substantially reduce the Netherlands’ one million users of antidepressants.

The revised “evidence based professional guidance” recommends that antidepressant treatment should be prescribed from the outset only if the patient’s depression “is accompanied by severe suffering or social dysfunctioning …
Adrenocortical Function in Pernicious Anemia
Authors: Maurice B. Strauss, Radford Brokaw
Journal: New England Journal of Medicine (1951)

THOMAS ADDISON'S clinical description of "idiopathic" anemia reveals so many manifestations identical to those encountered by him in disease of the suprarenal capsules1 that his failure to differentiate the two disorders clearly in his preliminary report in 18492 can readily be understood. That temporary adrenal insufficiency might be present in pernicious anemia in relapse was suggested a decade ago by the observations of Strauss and Fox,3 who noted: "... this behavior with regard to water and sodium exhibited by patients with Addisonian pernicious anemia is not unlike that shown by patients with Addison's disease of the suprarenal capsules."The purpose . . .
Avascular Necrosis of the Femoral and Humeral Heads after High-Dosage Corticosteroid Therapy
Authors: Walter G. Heimann, Robert H. Freiberger
Journal: New England Journal of Medicine (1960)

THE medical literature of the past ten years contains many reports of injurious side effects of systemic corticosteroid therapy.1 2 3 4 Osteoporosis and resulting vertebral fractures are almost the only skeletal changes caused by long-term corticosteroid therapy.5 Pietrograndi and Mastromarino6 described a single case of joint destruction after prolonged oral cortisone therapy. Sweetnam7 describes a case of unusually rapid and severe hip-joint arthropathy in a man who received oral and intra-articular administration of corticosteroids for rheumatic arthritis. The actual changes are described as "Charcot-like" in character and genesis. The damaging effects of intraarticular injections of cortisone have been amply described by Chandler . . .
Abstract 4073: Effects of metabolic and mitochondrial-targeted compounds on ovarian cancer cells
Authors: Daniel Chan, Keith Miskimins
Journal: Cancer Research (2011)

Abstract Ovarian cancer has the highest mortality rate of all the gynecological cancers in the United States, and is highly resistant to current forms of treatment. Metformin, a type II diabetes drug, and phenethyl isothiocyanate (PEITC), a component of cruciferous vegetables, were examined for their effects on ovarian cancer cell growth and survival. Although the exact mechanism of both drugs is not known, both have been found to inhibit complexes within the electron transport chain. Metformin is also known to activate the AMPK-LKB1 pathway, possibly downstream of complex I inhibition. We examined the effects of these compounds in vitro to evaluate the potential of electron transport chain inhibitors as novel therapies for ovarian cancer. To assess cell growth and death, hemacytometry with trypan blue exclusion was used in the ovarian cancer cell lines: SKOV3, OVCAR3, CAOV3, and PA-1. Induction of apoptosis was measured by Western blotting for intact and cleaved poly-ADP ribose polymerase (PARP). Western blotting was also used to determine endogenous levels of enzymes responsible for clearing reactive oxygen species (ROS). Levels of mitochondrial ROS production were measured by flow cytometry and confocal microscopy using the fluorescent probe MitoSOX. Metformin treatment was found to induce cell death in PA-1, arrest growth in OVCAR3 and CAOV3, and slow growth in SKOV3. PEITC treatment induced cell death through apoptosis in all tested cell lines at low micromolar concentrations. Metformin's inhibitory effects were partially reversed when growth medium was supplemented with succinate to bypass complex I. Low expression levels of anti-oxidant enzymes were also found to correspond with higher sensitivity to metformin and PEITC. Additionally, levels of mitochondrial ROS increased with treatment. Metformin and PEITC both show potential as ovarian cancer therapies. Complex I inhibition likely contributes to metformin's anti-cancer effects, as succinate supplementation was able to reverse growth inhibition. Additional work is necessary to determine if the increase in mitochondrial ROS is caused by electron transport chain complex inhibition and whether it is essential to the anti-cancer effects observed. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4073. doi:10.1158/1538-7445.AM2011-4073
AB0448 Vitamin d level is decreased in patients with takayasu’s arteritis, but is unassociated with the presence of fibromyalgia
Authors: F. Alibaz-Oner, O. Asmaz-Haliloglu, D. Gogas-Yavuz, M. Can, H. Direskeneli
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Takayasu arteritis (TAK) is a chronic, large-vessel arteritis predominantly affecting aorta, its major branches and the pulmonary arteries. Vitamin D, as a steroidal hormone, has recently been shown to have immunoregulatory and immunosuppressive effects. Low vitamin D levels are demonstrated in various autoimmune disorders. <h3>Objectives</h3> The association between Vitamin D deficiency and non-specific musculoskeletal pain, including fibromyalgia (FM) syndrome, is also controversial. The aim of this study is to investigate vitamin D levels in patients with TAK and to investigate the association between fibromyalgia and vitamin D deficiency in this group. <h3>Methods</h3> The study included 36 patients with TAK and 30 age and sex-matched healthy control subjects. Plasma 25-hydroxy vit D [25(OH) vit D] levels were measured with HPLC. "Deficiency" was defined as 25(OH) vit D level below 25 nmol/ liter and "insufficiency" as below 50 nmol/liter. All patients were examined for FM tender points and asked to complete new ACR 2010 FM questionnaire for FM. <h3>Results</h3> Plasma 25(OH) vitamin D were significantly lower in TAK patients (16.93±10.62 nmol/liter) than healthy controls (64.63±21.82 nmol/liter). The frequency of vitamin D deficiency was 83.3% in patients with TAK compared to 3.3% in controls. Plasma 25(OH) vit D levels were similar between clinically active and inactive patients. No association was also observed between vitamin D levels and the presence of FM (p=0.263 for 1990 Criteria, p=0.789 for ACR-2010 Criteria). <h3>Conclusions</h3> We observed a high prevalence of Vitamin D deficiency in patients with TAK, however without any association with the presence of FM. Vitamin D deficiency can be a predisposing factor for immune activation and we suggest monitorization and replacement of Vitamin D status in all TAK patients. <h3>Disclosure of Interest</h3> None Declared
ONE YEAR OPEN-LABEL TREATMENT WITH ALIROCUMAB 150 MG EVERY TWO WEEKS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS
Authors: Evan A. Stein, Jean Bergeron, Daniel Gaudet, Robert Weiss, Robert Dufour, Yunling Du, Feng Yang, Matthew Andisik, Albert Torri, Robert Pordy, Dan Gipe
Journal: Journal of the American College of Cardiology (2014)
Abstract LB-99: The novel IGF-IR/Akt-dependent anticancer activities of glucosamine are affected by PIK3CA hot-spot mutations and PTEN deletion.
Authors: Ju-Hee Kang, Ki-Hoon Song, Jeong-Seok Nam, Hye-Young Min, Ho-Young Lee, Sung-Dae Cho, Soo-Youl Kim, Seung Hyun Oh
Journal: Cancer Research (2013)

Abstract Background: Recent studies have shown that glucosamine inhibits the proliferation of various human cancer cell lines and downregulates the activity of COX-2, HIF-1α, p70S6K, and transglutaminase 2. Objective: Because the IGF-1R/Akt pathway is a common upstream regulator of p70S6K, HIF-1α, and COX-2, we hypothesized that glucosamine inhibits cancer cell proliferation through this pathway. Methods: Cell viability was assayed by MTT assay. Total RNA was isolated and reverse transcribed to cDNA for real-time PCR quantification of genes. Western blotting as performed for analyzing expression of proteins. Flow cytometry was performed for apoptosis and cell progression. Balbc/nu mice used in the study for validating results in vivo. Results: We found that glucosamine inhibited the growth of human non-small cell lung cancer cells in vitro and in vivo and negatively regulated the expression of IGF-1R and phosphorylation of Akt. In other types of cancer cells, including head and neck, breast, prostate, and colon carcinoma cell lines, glucosamine-sensitive cell lines exhibited a more significant decrease in IGF-1R and pAkt levels than glucosamine-resistant cell lines. Interestingly, most of the glucosamine-resistant cell lines have “hot-spot” mutations in PIK3CA, the p110α subunit of PI3K, or loss of PTEN, a negative regulator of Akt activation. In contrast, most of the glucosamine-sensitive cell lines have normal PIK3CA and PTEN genes. Glucosamine decreased the pAkt level through activation of IGF-1R more efficiently in the glucosamine-sensitive than in the glucosamine-resistant cell lines. Furthermore, co-treatment of cells with glucosamine and LY294002, a specific inhibitor of PI3K, significantly enhanced the anticancer effect of glucosamine in the glucosamine-resistant cell lines, whereas transient inhibition of PTEN by siRNA partially decreased the glucosamine sensitivity in the resistant and sensitive cell lines. Conclusions: Our results indicate that glucosamine is an effective inhibitor of the IGF-1R/Akt pathway and that glucosamine sensitivity of each cell line was affected by the mutation status of PIK3CA and PTEN. Citation Format: Ju-Hee Kang, Ki-Hoon Song, Jeong-Seok Nam, Hye-Young Min, Ho-Young Lee, Sung-Dae Cho, Soo-Youl Kim, Seung Hyun Oh. The novel IGF-IR/Akt-dependent anticancer activities of glucosamine are affected by PIK3CA hot-spot mutations and PTEN deletion. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-99. doi:10.1158/1538-7445.AM2013-LB-99
Abstract 3553: Modulation of pro-inflammatory signaling pathways by aging T-lymphocytes contributes to a more malignant phenotype in prostate epithelial cells
Authors: De Angulo Alejandra, Robert Faris, David Cavazos, Linda deGraffenried, Chris Jolly
Journal: Cancer Research (2012)

Abstract Prostate cancer risk is determined largely by age. While some studies have suggested that the slow growing rate of prostate cancer is responsible for the link between aging and prostate cancer, the role of aging T-cells in prostate cancer development remains largely unknown. The objective of this study is to determine how age-related changes in T-lymphocyte function contribute to prostate tumorigenesis. We hypothesized that age related changes in T-lymphocyte function, to a pro-inflammatory phenotype may promote prostate cancer development. For our studies we used the GPAT-1 KO mice model. The GPAT-1 KO mice have T-lymphocytes that mimic aged T-cells. Preliminary data shows that, in agreement with what has been seen in human aged T-cells, aging-mimic GPAT-1 KO T-lymphocytes generate more pro-inflammatory cytokines than T-lymphocytes from age matched wild-type mice. These cytokines turn on inflammatory pathways that stimulate proliferation, tissue disruption and tumor growth. A cytokine array was used to detect the relative protein levels of 40 different cytokines and chemokines in the sera from either young GPAT-1 knockout (KO), young wild-type (WT) or old mice (22 months). We observed a shift to a more pro-inflammatory cytokine profile in the GPAT-1 KO and old mice. Many of the same cytokines that were elevated in the sera from the old and GPAT-1 KO mice, such as IL-17 and IL-6, are also implicated in promoting prostate tumorigenesis primarily through induction of other inflammatory cytokines and transcription factors such as, NF-kB and STAT3. The objective of this study was to determine if the increased levels of pro-inflammatory cytokines in the sera from the GPAT-1 KO mice correlates to a more malignant phenotype in prostate epithelial cells. Malignancy in epithelial cells was assessed by the following phenotypical changes: Immortalization, anchorage independence, proliferation and invasiveness. Exposure to sera from the GPAT-1 KO mice promoted phenotypical changes in epithelial cells that are indicative of early tumorigenesis. Taken together our data suggests that pro-inflammatory cytokines in the sera from mice with aging T-lymphocytes may turn on pro-inflammatory pathways that contribute to a more malignant phenotype in prostate epithelial cells. This is the first study to use the GPAT-1 KO mice model to explore the relationship between aging T-lymphocytes, inflammation and prostate tumorigenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3553. doi:1538-7445.AM2012-3553
Defective Initiation of Oxidative Metabolism in Polymorphonuclear Leukocytes
Authors: Liana Harvath, Burton R. Andersen
Journal: New England Journal of Medicine (1979)

The polymorphonuclear leukocytes of a two-year-old boy who had multiple episodes of bacterial infections demonstrated defective oxidative metabolism with phagocytic, but not with soluble (non phagocytic), metabolic stimuli. We used a chemiluminescence assay to examine the patient's polymorphonuclear leukocyte responses to numerous particulate and soluble stimuli. The patient's polymorphonuclear leukocytes had substantially depressed chemiluminescent responses during phagocytosis of opsonized particles (latex, pneumococci, pseudomonas, streptococci and zymosan); however, we observed normal chemiluminescent responses when these leukocytes were stimulated with soluble agents (sodium fluoride, concanavalin A, cytochalasin E, calcium ionophore A23187 or phorbol myristate acetate). Polymorphonuclear leukocyte oxygen consumption and superoxide production were impaired during phagocytosis, even though phagocytosis was normal. In addition to the metabolic defect, this patient's polymorphonuclear leukocytes had depressed chemotactic and bactericidal activities. This study provides evidence that polymorphonuclear leukocytes have more than one mechanism for initiating oxidative metabolism. (N Engl J Med 300:1130–1135, 1979)
SAT0403 Patients with Chronic Low Back Pain Develop Over Time Positive Coping Strategies Include Striving for Normality, Dealing with Pain, Having High Levels of Physical Activity and Maintaining Social Connections: A Qualitative Study.
Authors: F. Bailly, V. Foltz, S. Rozenberg, B. Fautrel, L. Gossec
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Low back pain (LBP) is a frequent and costly syndrome which has an important impact on quality of life. There is a lack of knowledge in LBP on the patient's perspective from the broad bio-psychosocial approach. <h3>Objectives</h3> To gain further insight into patients' perspective on coping strategies in LBP. <h3>Methods</h3> The qualitative study involved participants with sub-acute or chronic LBP, who took part in four focus group discussions. Interviews were taped and transcribed verbatim, and all phrases were categorized and coded using thematic content analysis. <h3>Results</h3> The sample consisted of 25 patients, 11 men and 14 women; ages ranged 25-81 years and disease duration ranged 1-35 years. The interviews lead to the individualization of 5 major coping profiles. (a) The first coping profile was seen as negative: going over the limit and doing 'too much' related to negating the disease; ignoring symptoms and being over-active. (b) and (c) The 2 equilibrium statuses (endeavoring to lead a normal life; dealing positively with symptoms but reducing activities) included trying to be normal and minimizing the symptoms (including developing alternative ways of functioning), having social activities, and reinforcing physical activities to forget / lower pain. (d) and (e) The last 2 profiles were related to inhibition: being inhibited by anxiety, fear of the future and frustration; very reduced activities due to negative affects/depression. The only positive aspect of psychological impact was perceived better/more mature perspective on life. The coping profiles were evidenced in 4 major domains of life that patients had to cope with: pain, physical activities both at work and at home, psychological impact/emotions and social interactions. Due to apparent physical normality but reduced activities, patients described feeling perceived as "lazy" (perceived social discrimination). The patient verbatim indicated changes over disease duration with patients initially having negative affects and anxiety, then developing positive coping strategies. <h3>Conclusions</h3> This qualitative study gives insights into the patient's perspective in LBP and brings to light several previously ignored aspects in particular fear of the future, perceived social discrimination and burden of others' outlook on the disease, and coping strategies such as minimising symptoms to pursue a normal life including sports and leisure activities. <h3>Disclosure of Interest</h3> None Declared
P489 “VIRTUAL EXPERT” STAGING BY AUTOMATED MORPHOMETRY IMPROVES DIAGNOSIS AND PROGNOSTIC VALUE OF LIVER FIBROSIS
Authors: P. Cales, J. Chaigneau, G. Hunault, S. Michalak, C. Cavaro-Menard, J.B. Fasquel, S. Bertrais, M.C. Rousselet
Journal: Journal of Hepatology (2014)